3月5日 - ** 经纪公司杰富瑞（Jefferies）称，投资者对肥胖股的看法 "好坏参半"，但希望礼来公司LLY.N口服肥胖药的积极数据能让投资者重新关注这一领域。
** 礼来公司第三季度减肥药销售额低于 (link) 预期，导致该公司股价下跌 8%，但此后股价有所回升；其股价今年累计上涨 19%。
** 预计 (link)，LLY 将在 4 月份报告其肥胖症实验药物 orforglipron 的后期数据。
** 我们希望看到 LLY orfo 的积极数据有助于推动肥胖症对比数据的回升，并使投资者重新关注这一领域"--杰富瑞（Jefferies
** 除 LLY 外，Jefferies 还看好安进AMGN.O和 Structure TherapeuticsGPCR.O。
** 过去12个月中，AMGN上涨11.7%，GPCR下跌46.6%，LLY上涨14.9%。
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.